Ligand Pharmaceuticals LGND Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $115.09M-34.2% | $174.93M+25.5% | $139.38M+106% | $67.67M+41.0% | $47.99M-33.6% | ||
| $664.33M+18.9% | $558.59M+6.4% | $525.15M+196% | $177.35M+10.2% | $160.91M-12.5% | ||
| $53.38M-10.4% | $59.6M+3.5% | $57.56M+39.4% | $41.29M+7.3% | $38.49M+0.3% | ||
| $13.27M+45.4% | $9.13M-23.3% | $11.9M-23.2% | $15.49M+6.0% | $14.61M+3.5% | ||
| $865.42M+4.0% | $832.27M+10.4% | $753.92M+114% | $352.95M+14.1% | $309.32M-6.7% | ||
| $3.44M-3.6% | $3.57M+3.0% | $3.47M-4.6% | $3.63M+0.2% | $3.62M-76.1% | ||
| $101.54M0.0% | $101.54M0.0% | $101.54M0.0% | $101.54M0.0% | $101.54M-3.5% | ||
| $217.34M-3.6% | $225.44M-3.5% | $233.54M-6.6% | $250.13M-3.2% | $258.39M-3.1% | ||
| $1.53B-1.8% | $1.56B+5.7% | $1.48B+55.7% | $948.6M+4.8% | $905.44M-3.9% | ||
| $5.26M+62.6% | $3.24M-12.0% | $3.68M-57.1% | $8.58M+60.0% | $5.37M+2.5% | ||
| $621K0.0% | $621K0.0% | $621K+459% | $111K+9.9% | $101K-83.7% | ||
| $40.67M+8.6% | $37.45M+22.6% | $30.54M-52.8% | $64.73M+10.3% | $58.68M+58.1% | ||
| $3.94M+22.4% | $3.22M-99.4% | $526.6M+339% | $120.08M+9.3% | $109.9M-1.3% | ||
| 60M0.0% | 60M0.0% | 60M0.0% | 60M0.0% | 60M+299,900% | ||
| $594.74M-2.2% | $608.09M+5.2% | $578.22M+25.3% | $461.38M+1.1% | $456.53M-8.5% | ||
| $997.32M-2.0% | $1.02B+7.1% | $950.17M+14.9% | $827.31M+4.0% | $795.59M-4.2% | ||
| $1.53B-1.8% | $1.56B+5.7% | $1.48B+55.7% | $948.6M+4.8% | $905.44M-3.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Ligand Pharmaceuticals cover its short-term obligations?
- Its current ratio is 21.28 — current assets exceed current liabilities.
- Where does Ligand Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.